tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Apellis price target raised to $40 from $39 at Cantor Fitzgerald

Cantor Fitzgerald raised the firm’s price target on Apellis (APLS) to $40 from $39 and keeps an Overweight rating on the shares. The Geographic Atrophy market is stabilizing and the launch in C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis is under way, the analyst tells investors in a research note. Cantor believes the Empaveli C3G launch will go well.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1